1M6MYTD1Å5ÅMAKS.
Kurser indlæses...
Prognose
| Køb |
1 |
| Behold |
1 |
| Sælg |
0 |
Nyheder Til nyhedsfeedet
Aclarion: scan volume H1 2026 up 141%
Aclarion reports scan‑volume growth of 141% year‑on‑year and 71% sequentially for the first half of 2026, driven by rising adoption of the Nociscan platform. As of 30 June the company had USD 16.3 million in cash and was debt‑free; management says funds will last into H2 2027. Aclarion secured reimbursement from three major UK private insurers (Vitality, Axa, Aviva) and has launched a US market‑access program with PRIA Healthcare. The CLARITY study was expanded and a first interim readout is expected in 2026; the patent portfolio now comprises 65 granted and pending patents worldwide. » Mere på de.investing.com
Virksomhedstal
| (EUR) | juni 2026 | |
|---|---|---|
| Omsætning | 22,09 t | 34,76 % |
| Bruttofortjeneste | 7,27 t | 66,71 % |
| Nettoresultat | -2,41 mio. | 77,26 % |
| EBITDA | -2,35 mio. | 79,15 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 1,19 mio. € |
Antal aktier | 533,31 t |
Højeste/laveste i 52 uger | 10,37 € - 1,68 € |
| Udbytte | Nej |
Beta | 1,24 |
P/E (PE Ratio) | -0,34 |
PEG (PEG Ratio) | 0,00 |
K/I (PB Ratio) | 0,38 |
P/S (PS Ratio) | 16,55 |
Virksomhedsprofil
| Navn | ACLARION NEW DL-,00001 |
| CEO | Brent Ness |
| Medarbejdere | 11 |
